The biological rationale behind the combination rests on how cancer cells cope with DNA damage. ATR, or ataxia telangiectasia and Rad3-related protein kinase, is a central regulator of the DNA damage response. When replication stress causes DNA replication forks to stall, ATR stabilises those forks, delays the firing of late replication origins and activates S-phase and G2-M checkpoints, buying the cell time to repair damage before it divides. Blocking ATR therefore allows double-strand DNA breaks to accumulate, driving genomic instability and ultimately cell death. PARP1, meanwhile, is involved in repairing single-strand breaks during base excision repair, and PARP inhibitors such as olaparib work partly by trapping PARP1 on DNA, causing stalled replication forks to collapse into double-strand breaks.

Those double-strand breaks are normally repaired by the homologous recombination repair pathway, in which the tumour suppressor proteins BRCA1 and BRCA2 play key roles. In tumours carrying BRCA1/2 mutations, homologous recombination is defective, so PARP inhibitors kill the cells through synthetic lethality: two independent weaknesses that are individually survivable but lethal together. PARP inhibition also increases replication stress, making tumour cells increasingly dependent on ATR for survival. Preclinical work had shown selective synergy between ceralasertib and olaparib in BRCA-deficient and ATM-deficient models, and in most models of acquired PARP inhibitor resistance, raising hopes that the pairing could both deepen responses and overcome resistance in the clinic.

The trial, registered as NCT02264678, was a modular, open-label, multicentre study. In the dose-escalation phase, Part A1 tested ceralasertib alone at 80 mg twice daily or 160 mg once daily in 13 patients, while Part A2 escalated ceralasertib in combination with olaparib across 67 patients with advanced solid tumours. Dose expansion then followed in two breast cancer cohorts: Part B3 enrolled 37 patients with BRCA1/2-mutated, HER2-negative breast cancer who were PARP inhibitor-naive, and Part B4 enrolled 25 patients with BRCA1/2 wild-type triple-negative breast cancer. All expansion patients received the recommended Phase 2 dose until disease progression or discontinuation criteria were met.

The safety findings shaped the final dosing regimen. No dose-limiting toxicities occurred with ceralasertib monotherapy, but haematological toxicity emerged as the limiting factor when the two drugs were combined. Dose-limiting toxicities appeared in several escalation cohorts, predominantly involving neutropenia and thrombocytopenia, and attempts to push the ceralasertib dose higher or extend the number of dosing days proved intolerable. The recommended Phase 2 dose was set at ceralasertib 160 mg once daily on days 1 to 7 of each 28-day cycle, plus olaparib 300 mg twice daily given continuously. At this schedule, tolerability was illustrated by limited dose reductions and discontinuations, with a median relative dose intensity of 100 percent for ceralasertib in the expansion cohorts.

Across the expansion cohorts, treatment-emergent adverse events were nearly universal, affecting 97.3 percent of patients in Part B3 and 96.0 percent in Part B4, but grade 3 or worse events were less frequent, at 43.2 percent and 36.0 percent respectively. The most common severe toxicities were haematological: anaemia and neutropenia predominated in the BRCA-mutant cohort, while anaemia, thrombocytopenia and neutropenia appeared in the triple-negative cohort. Adverse events led to discontinuation in only a small minority of patients, two of 37 in Part B3 and one of 25 in Part B4, and no deaths from adverse events occurred in Part B3. The investigators concluded that no new safety signals were observed beyond those already known for each drug class.

The efficacy results revealed a striking split between the two expansion cohorts. In Part B3, 14 of 37 patients, or 37.8 percent, achieved a confirmed objective response, comprising one complete response and 13 partial responses, with a median duration of response of 9.8 months. Among the 30 patients whose BRCA1/2 mutation was centrally confirmed by next-generation sequencing, the response rate rose to 40.0 percent, the median duration of response reached 11.0 months, and median progression-free survival was 9.0 months. Median overall survival in this centrally confirmed group was 26.2 months. In sharp contrast, Part B4 produced no objective responses at all among patients with BRCA wild-type triple-negative breast cancer lacking homologous recombination repair mutations, with median progression-free survival of just 3.1 months.

Pharmacokinetic and pharmacodynamic analyses added mechanistic texture to the clinical findings. Ceralasertib was rapidly absorbed, reaching peak plasma concentrations within about an hour and a half, and exposures at both 160 mg once daily and 80 mg twice daily provided 24-hour coverage over the concentration required for 90 percent ATR inhibition. When the drugs were combined, single-dose ceralasertib exposure was modestly reduced compared with monotherapy, and ceralasertib did not accumulate at steady state. In paired tumour biopsies, levels of phosphorylated RAD50, a pharmacodynamic biomarker of DNA damage response activation, increased on treatment in all three evaluable samples, alongside rises in the DNA damage markers gamma-H2AX and phosphorylated CHK1, confirming target engagement, although the small sample size limited interpretation.

Exploratory biomarker work examined whether ATM status or expression of Schlafen-11, an emerging predictor of sensitivity to DNA-damaging therapy, could identify responders. Responders showed a higher proportion of ATM-low tumours than non-responders, and median SLFN11 H-scores were lower in patients achieving complete or partial responses than in those with stable or progressive disease, with 85.7 percent of responders classified as SLFN11-low. However, neither marker was strongly associated with clinical outcome, and the authors note that predictive biomarkers for ceralasertib remain to be elucidated, partly because replication stress, the key hypothesised predictor of ATR inhibitor sensitivity, still cannot be measured accurately in clinical tissue samples.

The authors place their findings in context by comparing them with landmark PARP inhibitor monotherapy trials in BRCA-mutated metastatic breast cancer, where median progression-free survival has ranged from 4.0 to 8.6 months and response rates have varied widely depending on prior platinum exposure. Without a monotherapy comparator arm, the contribution of ceralasertib to the observed activity cannot be conclusively determined, and the parallel randomised VIOLETTE study found no significant progression-free survival benefit from adding ceralasertib to olaparib in triple-negative breast cancer, possibly because haematological toxicity forced a relatively low ceralasertib dose. Nevertheless, the combination demonstrated preliminary activity with manageable safety in PARP inhibitor-naive patients with BRCA1/2-mutated HER2-negative breast cancer, and the authors argue that further work should identify which patient groups, defined by prior PARP exposure, specific mutations or biomarkers, are most likely to benefit from adding ATR inhibition to PARP therapy.

Subject of Research: Phase 1 trial of the ATR inhibitor ceralasertib combined with the PARP inhibitor olaparib in advanced solid tumours and breast cancer

Article Title: Safety and efficacy of ceralasertib, an ATR kinase inhibitor, combined with olaparib: dose escalation in advanced solid tumours and dose expansion in advanced breast cancer

Article References: Lopez, J. S., Im, S.-A., Postel-Vinay, S., Campone, M., El-Khoueiry, A. B., Abida, W., Arkenau, T., Lee, K.-W., Rha, S. Y., Jodrell, D. I., Roylance, R., Irurzun-Arana, I., Jones, G. N., Lukashchuk, N., Stephens, C., Norris, C., Loembé, A.-B., Dean, E., & Krebs, M. G. (2026). Safety and efficacy of ceralasertib, an ATR kinase inhibitor, combined with olaparib: dose escalation in advanced solid tumours and dose expansion in advanced breast cancer. British Journal of Cancer. https://doi.org/10.1038/s41416-026-03601-z

Image Credits: AI Generated

DOI: 10.1038/s41416-026-03601-z

Keywords: ceralasertib, olaparib, ATR inhibitor, PARP inhibitor, BRCA1/2, breast cancer, triple-negative breast cancer, DNA damage response, replication stress, Phase 1 trial, synthetic lethality, targeted therapy

The review, authored by Guodong Sun, Ronghua Huang, and Chuang Wu of Lanzhou University, synthesizes evidence across epidemiology, imaging, molecular biology, and artificial intelligence to make a single, pointed argument: the future of ovarian cancer early detection lies not in broader testing but in smarter testing. Rather than applying the same battery of tests to every woman regardless of her underlying risk, the authors contend that detection efforts should be risk-adapted, concentrating resources and diagnostic intensity on women whose hereditary, epidemiologic, or clinical profiles place them at elevated risk, while reserving symptom-triggered triage and structured diagnostic pathways for the general population. This reframing treats early detection not as a single test but as a designed clinical pathway in which each component has a defined role, a defined population, and a defined intended use.

Central to this argument is an evolving understanding of disease biology. High-grade serous carcinoma, the most common and lethal subtype of ovarian cancer, is now widely understood to frequently originate not in the ovary itself but in the distal fallopian tube, where serous tubal intraepithelial carcinoma lesions can precede invasive disease. This fallopian tube precursor paradigm has reshaped prevention, most visibly in the adoption of risk-reducing salpingo-oophorectomy for carriers of pathogenic BRCA1 or BRCA2 variants, and it has also reshaped thinking about detection. If the window between precursor lesion and metastatic spread is biologically narrow and clinically silent, then a screening strategy calibrated to the ovary alone may be looking in the wrong place at the wrong time. The review emphasizes that any credible detection framework must be built on this biological reality rather than on the anatomical assumptions of an earlier era.

Risk heterogeneity is the second pillar of the rethinking. Women with hereditary susceptibility, particularly those carrying BRCA1 or BRCA2 mutations and other homologous recombination repair gene variants, face lifetime risks and age distributions that differ sharply from those of the general population. For these women, intensive surveillance and, more decisively, preventive surgery occupy a distinct clinical space that population screening never could. Beyond genetics, epidemiologic factors such as age, family history, reproductive history, endometriosis, and increasingly polygenic risk scores can stratify the population into tiers with meaningfully different disease probabilities. The review argues that polygenic risk scores, while not yet ready for routine deployment, illustrate the direction of travel: a quantified, individualized estimate of risk that determines who should be watched, how closely, and with which tools.

For the general population, where universal screening has failed, the review points to symptom-triggered triage as the most realistic near-term strategy. Ovarian cancer is not truly asymptomatic; bloating, pelvic or abdominal pain, early satiety, and urinary urgency are common in early disease but nonspecific. Structured triage pathways that prompt clinicians to consider ovarian cancer when these symptoms persist, and to route patients promptly into standardized diagnostic evaluation, aim to shorten the interval between first presentation and definitive assessment. The value of this approach depends less on any single test than on the discipline of the pathway itself, which is precisely the review’s broader thesis: tools succeed when embedded in structured diagnostic pathways rather than used as isolated tests.

Within those pathways, the established diagnostic toolkit retains a central but carefully bounded role. Cancer antigen 125, the most widely used serum biomarker, remains limited by modest sensitivity for early-stage disease and by elevation in numerous benign conditions, but its performance improves substantially when interpreted in context, particularly after menopause and in combination with human epididymis protein 4 in algorithms such as the Risk of Ovarian Malignancy Algorithm. On the imaging side, the International Ovarian Tumor Analysis models and the Ovarian-Adnexal Reporting and Data System, known as O-RADS, have brought standardization to ultrasound interpretation, converting subjective pattern recognition into risk categories that guide referral and surgical planning. Multimodal indices such as the Assessment of Different NEoplasias in the adneXa model combine clinical information, serum markers, and ultrasound features to estimate malignancy probability before surgery. The review’s verdict on these tools is measured: they are most valuable as components of a defined sequence of assessment, not as standalone screening tests, and their incremental clinical utility depends on how and where they are deployed.

The most technically ambitious portion of the review surveys the emerging biomarker landscape, and here the authors are deliberately cautious. Cell-free DNA methylation assays, which detect tumor-derived epigenetic signatures circulating in blood, offer a plausible route to earlier and more specific detection, and next-generation sequencing has made such assays technically feasible at scale. Cervicovaginal molecular sampling exploits the proximity of the upper genital tract to a readily accessible specimen site, raising the possibility of detecting malignant or premalignant signals from the fallopian tube and endometrium through routine swabs. Extracellular vesicle platforms aim to capture tumor-derived protein and nucleic acid cargo packaged in membrane-bound particles, while volatile organic compound analysis and other metabolomic approaches seek disease signatures in exhaled breath or serum. Atlas-guided biomarker discovery, drawing on comprehensive molecular maps of ovarian cancer subtypes, is expanding the catalogue of candidate targets, including proteins such as Yes-associated protein and YWHAB that have emerged from proteomic studies.

Artificial intelligence threads through nearly all of these emerging approaches. Machine learning models trained on imaging data, radiomics pipelines that extract quantitative texture features from ultrasound and magnetic resonance images, and multimodal systems that integrate imaging, serum markers, and clinical variables all promise performance beyond any single modality. The review acknowledges this promise but insists on a sober implementation standard: emerging tools remain investigational until they have undergone external validation in independent populations, formal intended-use evaluation that defines exactly which patients and clinical questions they address, integration into existing diagnostic pathways without creating bottlenecks or false reassurance, and demonstrated implementation readiness in real-world clinical settings. A biomarker that performs brilliantly in a retrospective case-control dataset but collapses in a prospective primary-care population has, in the authors’ framing, no clinical utility yet.

The overall message is one of disciplined optimism. Ovarian cancer early detection is moving toward a more biologically informed and clinically actionable framework, one in which hereditary risk stratification, symptom-triggered triage, standardized imaging, and selected molecular biomarkers are assembled into coherent pathways, and in which each new technology is judged by the incremental clinical utility it adds rather than by its novelty. The most credible future strategy, the review concludes, is not broader testing but smarter testing: risk-adapted design that concentrates intensity where risk justifies it, and pathway-defined deployment that ensures every test answers a specific clinical question for a specific population. For a disease that has resisted half a century of screening efforts, that shift in philosophy, from the volume of testing to the intelligence of its design, may prove to be the most consequential development in ovarian cancer early detection in a generation.

Subject of Research: Risk-adapted strategies and emerging biomarkers for the early detection of ovarian cancer

Article Title: Rethinking ovarian cancer early detection: risk-adapted strategies, diagnostic pathways, and emerging biomarkers

Article References: Rethinking ovarian cancer early detection: risk-adapted strategies, diagnostic pathways, and emerging biomarkers. (n.d.). https://doi.org/10.1186/s13048-026-02233-4

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02233-4

Keywords: ovarian cancer, early detection, risk-adapted strategies, diagnostic pathways, biomarkers, CA125, HE4, O-RADS, BRCA1/2, cfDNA methylation, artificial intelligence, fallopian tube precursor